Monitoring of omalizumab therapy in children and adolescents.

Autor:	Steiß JO; Zentrum für Kinderheilkunde und Jugendmedizin, Justus-Liebig-Universität Gießen., Schmidt A; Zentrum für Kinderheilkunde und Jugendmedizin, Justus-Liebig-Universität Gießen., Lindemann H; Zentrum für Kinderheilkunde und Jugendmedizin, Justus-Liebig-Universität Gießen., Rudloff S; Zentrum für Kinderheilkunde und Jugendmedizin, Justus-Liebig-Universität Gießen., Staatz A; BioTeZ Berlin-Buch GmbH., Strohner P; BioTeZ Berlin-Buch GmbH., Becher G; BecherConsult GmbH Berlin., Nährlich L; Zentrum für Kinderheilkunde und Jugendmedizin, Justus-Liebig-Universität Gießen., Zimmer KP; Zentrum für Kinderheilkunde und Jugendmedizin, Justus-Liebig-Universität Gießen.
Jazyk:	angličtina
Zdroj:	Allergologie select [Allergol Select] 2018 Sep 01; Vol. 2 (1), pp. 32-38. Date of Electronic Publication: 2018 Sep 01 (Print Publication: 2018).
DOI:	10.5414/ALX01337E
Abstrakt:	Background: Omalizumab is a successfully implemented supplementary therapy for improving asthma control in children aged 6 years and older with severe persistent allergic asthma. The dosage of omalizumab depends on body weight and IgE level, yet no parameter has been established to guide dosage changes during therapy. Clinical studies in patients with allergic asthma or allergic rhinitis revealed a clinically relevant improvement by using omalizumab leading to concentrations of free serum IgE reported to be lower than 50 ng/ml. Therefore, only the question concerning the concentrations of free IgE used in a therapy with omalizumab is regarded of clinical importance, while total IgE (free and omalizumab-bound IgE) increases during treatment. Patients and Methods: Ten patients, 8 to 17 years of age, received therapy with omalizumab due to severe allergic asthma. In addition, the patients had pronounced rhinoconjunctivitis, food allergy, insect sting allergy, and/or neurodermitis. The total IgE in the serum was measured in the patients 3 - 6 months before each omalizumab injection as a potential progress parameter (Sandwich-Immunoassay ADVIA Centaur). Results: Six months after beginning of the therapy with omalizumab, a significant decrease of the total IgE concentration was found, in comparison to the baseline values (p < 0.003). In all patients the tolerability of omalizumab was very good: there was a reduction in the frequency of the asthma exacerbations and rescue medications. All patients reported a clearly improved quality of life. Conclusions: A general increase in IgE was not observed in any of the children we treated with omalizumab. Apart from the development of routine assays to determine free serum IgE levels, the significance of the total serum IgE as a suitable control of an omalizumab therapy should be further investigated in controlled studies with regard to sensitivity and specificity. In order to only administer the lowest necessary dose of omalizumab especially in children and adolescents, the establishment of laboratory parameters (free IgE and/or total IgE) to adequately monitor the therapy is urgently needed. Patients undergoing an omalizumab therapy require medical supervision at close intervals. (© Dustri-Verlag Dr. K. Feistle.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu